Genflow Biosciences Share Discussion Threads

[luckyabbeygale] 21/1/2024 10:55

The bigger seller is no different to having Lanstead.
Not always a bad thing, since by the time the dilution has gone. You end up owning around 3 times as many shares.
This is what happened to me with my main share in Oriole and ended up going up from 0.08p to 0.35p.

[moneymunch] 21/1/2024 09:52

Another potential imminent non-dilutive award for Genflow, who were awarded a $50k prize in September 2023 along with a new collaboration with Magnaetus Therapeutics from the healthspan challenge and now go forward to the next stage of the challenge, where $1 million will be awarded in January 2024 for the most promising longevity therapies, followed by a grand prize of $5m in June. Gla ;-)


September 2023

Developing therapeutic agents reverse ageing and metabolic decline

Cary Depel; Paul Baldock; Guy Barry |

Magnaetus Therapeutics; Eric Leire, MD | Genflow Biosciences

Competition Sponsor: US National Academy of Medicine

Awardee Year: 2023



Magnaetus Therapeutics believes that in order for longevity measures to be most effective, lifespan increases must be twinned with supportive metabolic interventions. This will ensure the ultimate aim of greater quality, as well as quantity of life, for the increasing majority of our population that is overweight/obese.

To deliver on this aim, Magnaetus is working with Genflow Biosciences to develop peptide therapeutics based upon the multiple metabolic activities of a novel circulating protein. Serum levels of this hormone are increased by exercise and calorie restriction, and suppressed by ageing, obesity and inactivity. It exhibits endocrine effects across numerous aspects of the energy economy, acting to mimic the downstream benefits of exercise and calorie restriction.

Longevity is directly targeted through a feed-forward loop with mTOR suppression. This is coupled with additional capabilities, including appetite suppression, fat burning and insulin production/sensitivity. The discrimination of these activities is realised through selection of individual loops of the parent protein’s repeated helical structure, enabling tailoring of therapeutic response to patient needs through production of specific peptide therapeutics.

[moneymunch] 21/1/2024 09:09

Mrs Bauer's orderley disposal of her husbands 14.5m shares, announced in March 2023, is no doubt done, and no doubt led to the slide in share price to January's all time low of c1.4p during the year as impatient pi's offloaded as the share price continued its slide. Any recent sellers are probably those who are banking their profits, 20% up pre-funding news from 1.4p to c1.65p and 30% up on the latest news at 2p plus, all in the mix regardless and Genflow are now set for a very exciting year according to Eric and the team, with the expectation of lots of positive newsflow to drive the share price North in the coming days and weeks....full market interest and investor focus is turning this way and so every chance Genflow will be one of the star shares of 2024.....Right time, right place!!! Gla holders....On and most definetly UP!!! ( imho ) ;-)

[marmiesz] 20/1/2024 18:35

Agee with this though I'm not sure how much of an impact it will have. We seem to have a persistent seller who has been selling for most of the year. Until we are rid of them, any uplift in share price will be limited. The sooner they go the better. We should be trading in the 8-12p range, imo.Marmie

[kubera369] 20/1/2024 13:40

Expecting the year end share holder letter to come in next week as per Eric's New Year posting on linked inI see more rises next week as the share letter will add a lot more value and updates to what has already been mentioned this week Loads of newsflow should be updated then and the share price should gain new levels Good luck

[moneymunch] 20/1/2024 08:29

Longevity biotech collaborates with Revatis and EXO Biologics on new research into sarcopenia and SIRT6 MRNA delivery.

Longevity biotech Genflow Biosciences has teamed up with Revatis and EXO Biologics on two new longevity research programs, fueled by grants from the Government of Wallonia in Belgium. Genflow is developing gene therapies that target the aging process, with a focus on reducing and delaying age-related diseases.

One of the new research programs, conducted in collaboration with cell therapy company Revatis, is focused on addressing the issue of age-related muscle loss. With funding of €1.34 million, the three-year initiative aims to provide insights into the mechanisms of sarcopenia – the muscle deterioration associated with aging.

Simultaneously, Genflow and exosome-focused biotech EXO Biologics are embarking on a three-year scientific program focusing on mRNA delivery. Supported by a grant of €1.55 million, the initiative will explore an approach using exosomes to encapsulate and transport Genflow’s SIRT6 gene therapy. The ultimate goal is to enable the development of therapeutic interventions for Werner Syndrome, an accelerated aging condition, and other age-related conditions.

Dr Eric Leire, CEO of Genflow said that the new research programs will allow the company to make “meaningful advancements” in the field of longevity.

“Launching both of these programs represents a strategic move to enhance our research capabilities, while contributing to the understanding of age-related conditions,” he said.

Genflow is currently developing a pipeline of SIRT6 gene therapies, with three programs targeting Werner Syndrome, an aggressive form of non-alcoholic fatty liver disease (NASH), and pet longevity. The company’s lead compound is a suspension of an adeno-associated viral vector-based gene therapy based on a variant of the human SIRT6 gene, which is associated with longevity in centenarians.

Disclosure: First Longevity Ltd which operates this website (Longevity.Technology) has a commercial interest in Genflow Biosciences Ltd.

[kubera369] 19/1/2024 18:14

Mr and Mrs Bauer ?

[steg] 19/1/2024 16:53

I have been puzzled for a while by who has been selling for months now because for sure the selling brought us back from 5p to 1.5p and clearly is still going on, I won’t say because I don’t know 100% but I think it’s from 2 sources who did own a large % of Genf combined and are linked. Anyway whoever it is hopefully they will finish soon and we can get going in the right direction

[kubera369] 19/1/2024 15:42

News is incoming any day now as per Eric's announcement on the Genflow linked in account.I would only be buying

[gah123] 19/1/2024 14:39

Thanks holding for 5p+, will top up if it dips.

[pie chart] 19/1/2024 12:24

No you are in a good place. This is yet to be truly discovered and still under the radar.

[gah123] 19/1/2024 11:55

Or am I missing something

[gah123] 19/1/2024 11:52

Invested yesterday at 2p what a gem, can't believe it's so cheap. Anything under 20m mcap is a steal surely.

[moneymunch] 19/1/2024 07:39

Ditto, a PlusOne Coin Top Post, and don't forget potential news on Genflow's GF-4001 Non-Human Pipeline Anti-aging for veterinary use (dogs), highlighted and perhaps significant by Revatis's veterinary R & D. Gla ;-)

[northeast14] 19/1/2024 07:18

Steg- fantastic post! A great balanced deep dive into Genf there.
GL

[moneymunch] 18/1/2024 22:09

Revatis SA

Innovation in cellular therapy

Revatis is a Spin Off from the University of Liège, dedicated to regenerative medicine and cell therapy. Revatis is based on the scientific discoveries of Prof. D. Serteyn and Dr J. Ceusters and has solid intellectual property and exceptional know-how.

Revatis has a patented technology for obtaining multipotent stem cells from a muscle micro-biopsy. This technology is available for clinical applications in veterinary medicine and for research in human medicine.

In veterinary medicine, Revatis aims to produce autologous stem cells for therapeutic use in horses and companion animals. In human medicine, Revatis is positioning itself as a supplier of personalized stem cells for banking, research, organ-on-a-chip and 3D bioprinting.



.....

Exo Biologics

Unlocking the Potential of Exosomes: The Next Frontier of Nanomedicine
Exosomes are nanometer-sized vesicles containing bioactive molecules secreted by cells. They can be used for the targeted delivery of therapeutic agents.


Exosomes are specific extracellular vesicles that carry RNA, Lipids, and protein messengers, naturally released by various cells. They induce and modulate distinct effects on targeted cells. Depending on their cellular origin, exosomes can also be loaded with specific bioactive molecules, and they have a potency and targeting ability.

EXOB-001, Our Lead Product Candidate
EXOB-001 Investigational Medical Product (IMP) consists of a sterile suspension of allogeneic extracellular vesicles (EVs) derived from cultured human umbilical cord mesenchymal stromal cells (hMSCs).

Human MSCs are characterized by their ability to, among other things, secrete various growth factors and cytokines that modulate the immune system and promote tissue repair and regeneration.

[moneymunch] 18/1/2024 22:07

GenFlow Biosciences

1,413 followers
7h

GenFlow Biosciences (LSE: GENF) (OTCQB: GENFF) is thrilled to announce its partnership with Revatis SA and EXO Biologics in Groundbreaking Aging Research, Fueled by Two Major Research Grants 🧬

"The two research programs are a part of a broader innovation partnership that the Walloon Government has launched, dedicated to Advanced Therapy Medicinal Products (ATMPs). The partnership boasts a substantial budget of 81 million euros, a mix of 60% public funding and 40% private contributions from various companies, spread over three years. This initiative is a collaborative effort involving BioWin, the Health Cluster of Wallonia and the Public Service of Wallonia, representing a significant commitment to advancing medical research and development in the region."

Read more about the exciting new venture here:

#ageing #longevity #healthspan #smallcap

[steg] 18/1/2024 22:01

Could be an amazing recovery story this year when you consider we were just over 12p at ipo time 2 years ago, since then massive progress, patents, multiple new projects, up and coming human trial in NASH, FDA meeting scheduled, solid funding for the years ahead, mice trial data coming soon, cash in the bank, CEO owns over 40% of company and the list goes on and on, definitely not ramping as this is all factual and public knowledge. My only speculation is that we will very soon see institutional buying making the free float very very tight as Eric has made it clear and has now proven time and time again that he is very capable of raising funds via non dilutive funding grants. I can’t help but to feel that if 12p was fair two years ago with the huge progress now made and long term financial security of the business in what is fast becoming the hottest world wide market for all to see surely fair value is now 12p to 36p. This could be a life changing share for those prepared to have some patience all of course in my humble opinion as they say, meantime best of luck to investors prepared to hold long term

[moneymunch] 18/1/2024 19:54

12 months since a crucial patent application, not just for Genflow but a breakthrough for gene therapy and longevity research according to Eric, which could add massive value if awarded. It can take up to 2 years for approval, but the US Patent Office can award within 12 months if accelerated, and so news at anytime which would be truly transformational for all concerned. Gla :-)

"Genflow has expanded its intellectual property portfolio with a provisional patent application focusing on the SIRT6 gene editing. If granted, this patent could mark a significant breakthrough in gene therapy and longevity research."



1.20230018934

METHOD OF IN VIVO ADMINISTRATION OF THE CODING SEQUENCE OF THE SIRT6 GENE VIA ADENO-ASSOCIATED VIRUS

US - 19.01.2023
Int.Class
A61K 48/00
Appl.No 17865688

Applicant GENFLOW BIOSCIENCES SRL

Inventor Eric LEIRE

Methods for in vivo administration of the coding sequence of the sirt6 gene. In particular, methods that include the administration of adeno-associated virus vectors or recombinant adeno-associated virus vectors including the coding sequence of the sirt6 gene.

[northeast14] 18/1/2024 17:55

Lawson27- definitely be in a few papers and hopefully Eric will do an interview with proactive investors

[luckyabbeygale] 18/1/2024 16:21

From my stockwatch I have noticed an unusual amount of losses being cut on other stocks.
I wonder if any of that is for investing here.

[lawson27] 18/1/2024 16:01

No doubting we shall get mentioned in a few financials tomorrow

[northeast14] 18/1/2024 15:57

Tomorrow should be interesting also after people read this later

[kubera369] 18/1/2024 15:50

People just have to be crazy selling now as this is only going one way now as they transport Genflow to the launch pad and set the burners on fire